Biotech News

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

PROCEPT BioRobotics (PRCT)PROCEPT BioRoboticsEarnings

PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Related news

PROCEPT BioRobotics

Urology Robotics PROCEPT BioRobotics develops robotic systems for the surgical treatment of benign prostatic hyperplasia. Its technology is designed to standardize tissue removal while preserving outcomes across different prostate sizes and anatomies. Aquablation Therapy Aquablation uses a robotically controlled, heat-free waterjet to...

Recent company news

Stock data

Close
18.27 USD
Market cap
1.52B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States